Home / Treatments / Allergy Rx
Allergy Rx denials: what the review data shows
Independent reviewers have decided 31 published cases where an insurer denied Allergy Rx — and they overturned the insurer 58.1% of the time. A denial for Allergy Rx is a starting position, not a final answer.
Published decisions
31
2001–2026
Overturned
58.1%
18 denials reversed
Conditions behind allergy rx denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Resp Allergies | 9 | 66.7% |
| Allergy | 9 | 66.7% |
| Asthma | 4 | 50% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 27 | 66.7% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 4 | 0% |
Typical time to a decision
14 days
Most land between 4 and 19 days
Handled as urgent
48.4%
Expedited when a delay would cause harm
Recent direction
Rising
45.5% → 61.5% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for Neffy solution. According to a study, “Patients at a higher risk of anaphylaxis are often prescribed epinephrine intramuscular (IM) autoinjectors because the vast majority of anaphylactic events occur at home or in a community setting. However, epinephrine self-administration via autoinjectors for anaphylaxis is suboptimal because of lack of carriage and needle phobia, which may result in delayed administration or failure to use epinephrine at all. In a study of 190 patients prescribed epinephrine IM autoinjectors, only 30% of those who experienced an anaphylactic event actually used it.” This study found that delays or failure to self-administer epinephrine increase the risk of serious anaphylaxis-related complications.
Nature of Statutory Criteria/Case Summary: The patient’s parent has requested authorization and coverage for Auvi-Q 0.3 mg Auto-injector. Findings: The physician reviewer found that Epinephrine administration is a critical component of an individualized emergency action plan for patients at risk for anaphylaxis. The autoinjector should be portable, identifiable, safe, and effective. Safety technology to prevent injury after use contributes to safety and reliability. Optimal grip designs, tailored in size and/or shape to specific patient types, contribute to reliability and effectiveness. Auvi-Q offers improved portability than Epi-Pen in these aspects.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: Allergen-specific IgG4 testing has not been demonstrated in randomized controlled clinical trials to be effective for routine clinical care and is not recommended for the evaluation of IgE-mediated food allergies per expert panel guidelines due to lack of evidence. Also noted in the 2014 Joint Task Force Updated Food Allergy Practice Parameters, “allergen-specific IgG measurement…should not be used for the evaluation of food allergy”. Similarly, allergen-specific IgG testing is not included in recommendations for diagnosis of non-IgE mediated immunologic adverse reactions to foods.
Nature of Statutory Criteria/Case Summary: Allergen-specific IgG4 testing has not been demonstrated in randomized controlled clinical trials to be effective for routine clinical care and is not recommended for the evaluation of IgE-mediated food allergies per expert panel guidelines due to lack of evidence. Also noted in the 2014 Joint Task Force Updated Food Allergy Practice Parameters, “allergen-specific IgG measurement…should not be used for the evaluation of food allergy”. Similarly, allergen-specific IgG testing is not included in recommendations for diagnosis of non-IgE mediated immunologic adverse reactions to foods.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Allergy Rxwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.